CB2 Insights Inc (CSE:CBII) (OTMKTS:CBIIF), the medical cannabis research, data and education group, has extended the reach of its business with the launch of a new interactive dashboard for use by stakeholders.
The dashboard, accessed via the firm's website at https://cb2insights.ca/data, is free, and offers key patient insights derived from the firm's clinical operations.
It was created to answer hundreds of questions from global industry stakeholders, including government agencies and major research groups. It also allows users to submit additional data requests directly to CB2's research and data team.
"This new interactive tool will allow these groups to access the primary insights that they are requesting quickly and gain real-time results," Prad Sekar, the company's CEO, said in a statement.
"But with the millions of data points that we monitor, they also have the opportunity to discuss with us how they can receive more tailored results that match their needs. And more importantly, solidify CB2 Insights as one of the sole providers of these types of insights in this industry."
Tom Brogan, director at CB2 Insights added; "Accurate, structured data is at the center of everything healthcare companies do in this day and age. Access to the type of medical cannabis data that CB2 holds is not only rare, it is essential to truly transition these alternative treatments into mainstream healthcare. This new tool is certainly a powerful bridge to expedite that process across a wide range of industry stakeholders."
CB2 Insights owns one of the largest group of multi-state medical cannabis evaluation and education centers and operates in states such as Colorado, Massachusetts, Maryland, New Jersey, Pennsylvania, Connecticut and Maine.
Over 100,000 patients
Physicians, nurse practitioners and cannabis educators treat and support more than 100,000 patients each year across 60 different primary conditions.
With high patient diversity seeking treatment for everything from chronic pain to sleep disorders to anxiety and depression, CB2 Insights has access to anonymized and de-identified insights into one of the world’s largest and richest data sets derived from the point-of-care.
CB2 also offers comprehensive contract research organization (CRO) services including full-scale clinical trial management, trial design, monitoring and other key research functions used by licensed producers, multi-state operators and traditional pharmaceutical companies entering the medical cannabis space.
Shares in CB2 Insights added over 13% to stand at C$0.085 each.
---Updates for share price---
Contact the author at [email protected]